The global genomics market size was estimated at USD 15.48 billion in 2018 and is anticipated to expand at a CAGR of 8.6% over the forecast period. The growth of genomic data pool due research activities has enabled physicians, biologists, and patients to further investigate the genetic predisposition to certain diseases. Clinical application of this data pool is expected to play a major role in transforming the healthcare system with respect to the provision of more accurate, effective, and reliable disease management solutions.
Although clinical application of genomic data is at a nascent stage in present, the healthcare and research community are making attempts for effective integration of genetic information into clinical workflows. Several clinical centers, such as Stanford Health Care and other cancer research centers, have begun using the available genomic information to devise personalized treatment regime. This, in turn, helps in bridging the gap between translational research and clinical diagnosis and treatment.
Lucrative growth is anticipated regarding the implementation of human genetic studies into various public health programs such consumer wellness programs, population screening, and others. The programs are mainly aimed at optimizing preventive care for common chronic diseases such as cancer and heart disease.
Growing investment by government bodies, funding agencies, and biotechnology companies to accelerate genomic research is anticipated to have major ramifications on reshaping the genomics market. International funding bodies like NIH and Welcome Trust are engaged in providing funds for genetic studies, which in turn, is expected to fuel genomic studies in both developed as well as emerging countries.
One of the most important factors anticipated to impact this market is how much and to what extent the medical community will make the use of available genomic information in personalized medicine. Scientists are combining the data generated from sequencing with diagnostics, which has proven effective in enhancing personalized treatment landscape.
Generation of large amount of sequencing data has led to significant growth of functional genomics trend. Development of high-throughput technologies for gene as well as protein studies has supported the growth of this segment. Progress in the genomic industry from studying individual genes to entire genomes and proteomes within a relatively short time frame reflects the growth of this segment. Integration of high throughput solutions in functional genomics has offered the possibility of developing efficacious drugs with fewer adverse effects. Furthermore, use of behavioral genetic tool kits holds a significant potential for evaluation of competing hypotheses regarding modules and peculiarities of particular behavior.
Investigation of how individual targets communicate and respond within the molecular networks has helped elaborate functioning of biological processes at a cellular level. Pathway analysis has become an integral aspect in drug development and life sciences research. Research community uses pathway analysis to improve fundamental understanding of cellular and molecular biology. On the other hand, pharmaceutical companies implement network analysis for development of next-generation therapeutics. Pathway-based analysis has gained more attention after the emergence of genomics and personalized therapies.
This is mainly because genomics and personalized therapies aid in in-depth analysis of the ability to navigate signaling pathways and disease networks. The increasing information on these network analyses can be used to address the challenges faced in developing therapeutics and genetic assays to increase the chance of success in research and development. Several types of biological resources such as pathway databases, gene annotation databases, and gene ontology can be effectively used for pathway analysis
Miniaturization in the instruments used in genomic applications is expected to serve as a fillip for market growth. The advantages offered by these instruments include specificity, sensitivity, and automation for the development of point-of-care diagnostics. With the maturity in development of microfabrication technology, microfluidic systems are observed to be useful for different genomic detections. The major objective of these miniaturized instruments is the development of the point-of-care device.
Moreover, rising usage of impedimetric detection is one of the promising techniques for the instruments in this market. Advancements in circuits and systems are seen to be driving the market with a technical revolution in the omics era.
Uptake of cloud based solutions which effectively and robustly manage the parallelization and distribution of input data and user code on a large number of computer nodes are attributive for estimated growth in the market. Cloud computing provides a very clear advantage of performing tasks across different parallel computing nodes and processors coupled with significant reduction in the waiting time. Introduction of cloud computing environment for processing NGS generated data has played a great role as a driving force for current genomics market.
NGS-based services have witnessed a continuous growth since its introduction. The demand for these services would remain strong with the expansion of the customer base from being limited to academic and research centers to CROs, biotech and pharma players.
With the decrease in sequencing costs and improvements in informatics, genetic solutions are now widely accessible in various sectors ranging from small labs to clinical settings. Key usage segments consist of pharmaceutical and biotechnology companies, hospitals and clinics, academic and government institutes, clinical research, and other end users. Among these, pharmaceutical and biotechnology companies held the largest share owing to increase in the number of genetic research studies that aimed at improving drug discovery process and development of efficacious drugs with fewer side effects.
Moreover, biotechnology companies are effectively using gene editing tools to meet the unmet needs of patients through development of recombinant and genetically engineered products. Other end users that include Direct-To-Consumers (DTC), agriculture research institutes, and forensic centers is estimated to hold the lowest share in the current market. This is primarily because of less and slow usage of genetic tools within these entities. However, in the coming years, this segment is expected to witness lucrative growth owing to fact that DTC is receiving significant attention amongst consumers, government, and genomic companies.
North America held the largest market share of overall market in 2018. Increasing investment on research by government organizations, rising patient awareness, and availability of sophisticated healthcare infrastructure has led to the increased technological advancements in this market. Local presence of key players such as Affymetrix, Inc.; Bio-Rad Laboratories, Inc.; Agilent Technologies; GE Healthcare; Illumina, Inc.; Cepheid, Inc.; and Danaher Corporation can also be attributed to the high market share.
Asia Pacific is expected to witness the fastest growth in the coming years. Developing infrastructure in these countries has led to the increased demand for biomarkers for diagnostics purposes. The market is anticipated to grow owing to increase in adoption and awareness about a number of genomics technologies in the emerging countries such as China and India for detection, treatment, and prognosis of various genetic disorders such as diabetes, cancer, and others.
There are several interesting human genome sequencing projects being carried out, one of the most recent project is Genome Asia 100K (GA 100K). Under this project, 100,000 Asians genomes will be sequenced and analyzed, which will help accelerate population-specific medical advances and precision medicine.
Major players include Thermo Fisher Scientific, Inc.; Agilent Technologies; Bio-Rad Laboratories, Inc; Danaher; BGI; F. Hoffmann-La Roche Ltd..; Illumina, Inc; Pacific Biosciences; Oxford Nanopore Technologies.; 23andMe, Inc, Foundation Medicine, Inc, and Myriad Genetics, Inc.
Companies are embracing the trend of offering varied reagents that simplify workflow process. For instance, in January 2017, BD launched Precise WTA Reagents for accurate and simple quantification of genetic information form single cell analysis. Moreover, in July 2016, SGI-DNA a company involved in synthetic genomics entered into a distribution agreement with VWR. Under this agreement, VWR provides the companies with reagents in North America and Europe.
Thus high saturation owing to a wide range of reagents and consumables has led players into adopting different strategies to sustain in the market. Agilent has also broadened its offering of CRISPR RNA libraries for genome based research.
Base year for estimation
Actual estimates/Historical data
2014 - 2017
2019 - 2025
Revenue in USD Million & CAGR from 2019 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, U.K., Germany, Japan, China, Brazil, South Africa
Revenue forecast, company share, competitive landscape, growth factors, and trends
15% free customization scope (equivalent to 5-analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country level and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this report, Grand View Research has segmented the global genomics market report on the basis of application and technology, deliverables, end use, and region:
Application & Technology Outlook (Revenue, USD Million, 2014 - 2025)
Proteomics tools (2-D PAGE; yeast 2-hybrid studies)
Chromatin immunoprecipitation (ChIP & ChIP-Seq)
Methylated DNA immunoprecipitation (MeDIP)
High resolution melt (HRM)
Chromatin accessibility assays
Deliverables Outlook (Revenue, USD Million, 2014 - 2025)
Consumables & Reagents
Core Genomics Services
Biomarker Translation Services
End use Outlook (Revenue, USD Million, 2014 - 2025)
Pharmaceutical and Biotechnology Companies
Hospitals and Clinics
Academic and Government Institutes
Other End Users
Regional Outlook (Revenue, USD Million, 2014 - 2025)
Middle East and Africa (MEA)
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."